November 1st 2022
Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.
October 31st 2022
Schlechter discussed the design of the TACTIC-2 clinical trial for patients with HER2-positive solid tumors.
October 13th 2022
The chief medical officer of Triumvira Immunologics discussed the company’s future plans.
September 26th 2022
The chief medical officer of Triumvira Immunologics discussed how TAC01-HER2 could address unmet needs in treating solid tumors.
September 24th 2022
The deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.
September 22nd 2022
The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.
September 20th 2022
The deputy director of the Masonic Cancer Center discussed the preclinical findings of his study on a TriKE engager and NK cells.
September 19th 2022
Hong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.
September 17th 2022
Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.
September 13th 2022
Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.